Global Non-Small Cell Lung Cancer Market Assessment, By Type [Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Others], By Treatment Type [Chemotherapy, Targeted Therapy, Immunotherapy], By Drug Class [Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/PD-L1 Inhibitor], By Distribution Channel [Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Pharmacy], By Region, Opportunities and Forecast, 2016-2030F
Global non-small cell lung cancer market size was valued at USD 10.6 billion in 2022, and is expected to reach USD 21.9 billion in 2030, with a CAGR of 9.5% for the forecast period between 2023 and 2030F.
Home>Industry Reports>Global Non-Small Cell Lung Cancer Market Assessment, Opportunities and Forecast, 2016-2030F
Global non-small cell lung cancer market size was valued at USD 10.6 billion in 2022, and is expected to reach USD 21.9 billion in 2030, with a CAGR of 9.5% for the forecast period between 2023 and 2030F. The global non-small cell lung cancer market is a dynamic landscape characterized by ongoing advancements in treatment modalities, diagnosis, and a growing understanding of the disease.
NSCLC represents a predominant form of lung cancer, constituting approximately 85% of all lung cancer cases. For instance, according to the 2023 statistics published by ACS, about 238,340 new cases of lung cancer are expected to be diagnosed in 2023. This market is shaped by a complex interplay of factors, including technological innovations, evolving therapeutic strategies, and increasing awareness of personalized medicine. Advancements in precision medicine have revolutionized NSCLC treatment, with a shift towards targeted therapies and immunotherapies tailored to specific genetic mutations or biomarkers present in individual patients.
The emergence of immune checkpoint inhibitors and targeted therapies, such as EGFR and ALK inhibitors, has significantly transformed the treatment paradigm, offering improved outcomes and reduced side effects compared to traditional chemotherapy. Moreover, the landscape is continually evolving with ongoing research and development initiatives, aiming to discover novel therapeutic targets, innovative combination therapies, and diagnostic tools for early detection. Biomarker-driven therapies, liquid biopsies, and companion diagnostics play a pivotal role in treatment selection, enabling more precise and effective interventions for patients. Market competition is intense, with pharmaceutical companies investing significantly in research and clinical trials to introduce novel therapies and expand their product portfolios. However, challenges persist, including high treatment costs, access disparities, and the need for more comprehensive screening programs to diagnose NSCLC at earlier stages.
Strategic Partnership Between Key Players
In the dynamic landscape of the global non-small cell lung cancer market, strategic collaborations have emerged as pivotal. Major players, such as pharmaceutical firms and biotech companies, are forging impactful partnerships. Recent alliances between leading diagnostic technology providers and pharmaceutical giants aim to revolutionize treatment through precision medicine and innovative therapies. These collaborations focus on joint research, development, and commercialization, leveraging collective expertise to introduce novel treatments and diagnostic solutions.
This strategic convergence fosters a synergetic approach, propelling advancements in personalized medicine, improving patient outcomes, and reshaping the paradigm of non-small cell lung cancer management globally. For instance, Bristol Myers Squibb, finalized the acquisition of Turning Point Therapeutics on March 6, 2022. Turning Point Therapeutics is a clinical-stage precision oncology company with a lineup of internally developed investigative medications aimed at overcoming major constraints of current cancer treatments. This acquisition expanded Bristol Myers Squibb's oncology portfolio by incorporating late-stage precision oncology asset.
Technological Advancements
The global non-small cell lung cancer market has seen significant technological advancements, revolutionizing treatment approaches. Targeted therapies, such as immunotherapies and precision medicine, have reshaped the landscape. Immunotherapies like checkpoint inhibitors (PD-1/PD-L1 inhibitors) have shown remarkable efficacy in managing advanced NSCLC by enhancing the body's immune response against cancer cells. Additionally, the emergence of personalized medicine, utilizing genetic testing to identify specific mutations or biomarkers, has led to the development of drugs tailored to individual patients.
Liquid biopsies, a minimally invasive diagnostic technique, is gaining prominence for monitoring treatment response and detecting mutations. Furthermore, advancements in imaging technologies like PET scans and MRI have improved early detection and monitoring of NSCLC. In January 2023, Novocure announced the LUNAR study, which assessed the safety and effectiveness of Tumor Treating Fields (TTFields) in combination with standard treatments for stage 4 non-small cell lung cancer (NSCLC) after progression following or during platinum-based therapy, successfully achieved its main objective.
New Innovations
The non-small cell lung cancer market has witnessed groundbreaking innovations aimed at revolutionizing treatment. Immunotherapies like checkpoint inhibitors, such as Pembrolizumab and Nivolumab, have reshaped the landscape by targeting specific proteins to enhance the immune response against cancer cells. Furthermore, targeted therapies like Osimertinib have shown efficacy in specific genetic mutations like EGFR, improving outcomes for patients. Liquid biopsy techniques are emerging, offering less invasive methods to detect genetic mutations, aiding in treatment decisions.
Advancements in precision medicine and biomarker testing are fostering personalized treatment approaches, optimizing therapies for individual patients. Additionally, advancements in combination therapies and innovative drug delivery systems are showing promising results in enhancing treatment efficacy and reducing side effects. During December 2022, the FDA in the United States, provided accelerated approval to Mirati's Krazati (adagrasib), offering a targeted treatment for adult patients diagnosed with KRAS-mutated locally advanced or metastatic non-small cell lung cancer.
Increasing Investment by Companies in Developing Effective Therapies
The global non-small cell lung cancer market is witnessing a significant uptick in investment by companies aimed at developing more effective therapies. This surge in investment underscores a commitment to advancing the field of oncology and addressing the unmet medical needs of patients. Companies are allocating resources to research and develop innovative treatments that encompass targeted therapies, immunotherapies, and precision medicine approaches. The increased focus is driven by a growing understanding of the molecular complexities of non-small cell lung cancer, leading to the identification of new drug targets and treatment strategies.
For example, during January 2023, DeuterOncology, a clinical-stage pharmaceutical firm, concluded a Series A financing round, securing approx. USD 6.1 million (EUR 5.65 million). This investment empowers the company to commence the phase I clinical investigation for its primary product DO-2, an enhanced MET kinase inhibitor designed as a promising targeted therapy for lung cancer, striving to be a top-tier treatment option. Recently, MET inhibitors have gained approval for treating patients with Non-Small Cell Lung Cancer (NSCLC) exhibiting the MET exon 14 skipping mutation.
Impact of COVID-19
The growth of the non-small cell lung cancer market has been significantly impacted by COVID-19. Specifically, the pandemic led to the cessation of over 200 interventional studies, as indicated by clinicaltrials.gov until July 2021, resulting in a deceleration of market expansion. Nevertheless, with the easing of restrictions and the resumption of services, there has been a renewed emphasis on conducting clinical trials for non-small cell lung cancer treatment. Notably, in October 2022, Daiichi Sankyo, Inc., in collaboration with AstraZeneca, initiated a Phase II clinical trial to assess the safety and effectiveness of trastuzumab deruxtecan in treating HER2-mutated metastatic non-small cell lung cancer (NSCLC). These endeavors are anticipated to propel market growth throughout the projected period.
Global Non-Small Cell Lung Cancer Market: Report Scope
“Non-Small Cell Lung Cancer Market Assessment, Opportunities and Forecast, 2016-2030F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative & quantitative assessment of the current state of the global non-small cell lung cancer market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, COVID-19 impact, opportunities, and forecast between 2023-2030F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.
|
Report Attribute |
Details |
|
Base Year of the Analysis |
2022 |
|
Historical Period |
2016-2021 |
|
Forecast Period |
2023-2030F |
|
Projected Growth Rate |
CAGR of 9.5% between 2023 and 2030F |
|
Revenue Forecast in 2030 |
USD 21.9 billion |
|
Units |
Revenue in USD billion |
|
Segments Covered |
Type, Treatment Type, Drug Class, Distribution Channel and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, Middle East, and Africa, South America |
|
Key Companies Profiled |
Novartis AG, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Sanofi, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc., Agennix AG. |
|
Customization Scope |
15% free report customization with purchase |
|
Pricing and Purchase Options |
Avail the customized purchase options to fulfil your precise research needs |
|
Delivery Format |
PDF and Excel through email (subject to the license purchased) |
In this report, global non-small cell lung cancer market has been segmented into the following categories:
1.1. Squamous Cell Carcinoma
1.2. Large Cell Carcinoma
1.3. Adenocarcinoma
1.4. Others
2. By Treatment Type
2.2. Targeted Therapy
2.3. Immunotherapy
3. By Drug Class
3.2. Epidermal Growth Factor Receptor Blocker
3.3. Kinase Inhibitor
3.4. Microtubule Stabilizer
3.5. Folate Antimetabolites
3.6. PD-1/ PD-L1 Inhibitor
4.2. Drug Store & Retail Pharmacy
4.3. Online Pharmacy
5. By Region
5.1. North America
5.2. Europe
5.3. Asia-Pacific
5.4. South America
5.5. Middle East & Africa
Key Players Landscape and Outlook
The non-small cell lung cancer market is characterized by fragmentation and competitiveness, featuring numerous major players. These companies are implementing diverse strategic approaches like collaborations, partnerships, new product introductions, and other initiatives to maintain their standing in the market. The market features a competitive landscape with several key players driving innovation and therapeutic advancements. Immunotherapies and targeted therapies remain a focus, with ongoing clinical trials and the development of combination therapies. The market outlook is promising, with an increasing emphasis on early detection methods, liquid biopsy technologies, and the exploration of innovative drug delivery systems. Collaboration between key players, academic institutions, and biotech firms continues to drive the evolution of treatment options, underscoring a future of diversified, more effective, and personalized therapies for NSCLC patients.
In June 2022, the European Commission granted approval to Novartis's Tabrecta (capmatinib) as a standalone treatment for adults dealing with advanced non-small cell lung cancer, necessitating systemic therapy after prior treatment with immunotherapy and/or platinum-based chemotherapy.
Key Players Operating in Global Non-Small Cell Lung Cancer Market are:
· Novartis AG
· F. Hoffmann-La Roche Ltd.
· Bristol-Myers Squibb Company
· Pfizer Inc.
· AstraZeneca
· Eli Lilly and Company
· Merck & Co., Inc.
· Boehringer Ingelheim International GmbH
· Sanofi
· Astellas Pharma Inc.
· Takeda Pharmaceutical Company Limited
· Bayer AG
· Eli Lilly and Company
· GlaxoSmithKline plc.
· Agennix AG
Markets and Data reports answer the following questions:
• What is the current and future market size of the product/service in question globally or specific to different countries?
• How are the markets divided into different product/service segments and each segment's market size and growth?
• What is the market potential of different product segments and their investment case?
• How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
• What is the business environment and regulatory landscape specific to the product/service?
If you can't find what you're searching for or have any custom requirements for global non-small cell lung cancer market, you may approach our team at info@marketsandata.com.
Table of Contents
1. Research Methodology
2. Project Scope & Definitions
3. Impact of COVID-19 on the Global Non-Small Cell Lung Cancer Market
4. Executive Summary
5. Global Non-Small Cell Lung Cancer Market Outlook, 2016-2030F
5.1. Market Size & Forecast
5.1.1.By Value
5.1.2.By Volume
5.2. By Type
1.1.1.Squamous Cell Carcinoma
1.1.2.Large Cell Carcinoma
1.1.3.Adenocarcinoma
1.1.4.Others
5.3. By Treatment Type
1.1.5.Chemotherapy
1.1.6.Targeted Therapy
1.1.7.Immunotherapy
5.4. By Drug Class
1.1.8.Angiogenesis Inhibitor
1.1.9.Epidermal Growth Factor Receptor Blocker
1.1.10. Kinase Inhibitor
1.1.11. Microtubule Stabilizer
1.1.12. Folate Antimetabolites
1.1.13. PD-1/ PD-L1 Inhibitor
5.5. By Distribution Channel
1.1.14. Hospital Pharmacy
1.1.15. Drug Store & Retail Pharmacy
1.1.16. Online Pharmacy
5.6. By Region
5.6.1.North America
5.6.2.Europe
5.6.3.Asia-Pacific
5.6.4.South America
5.6.5.Middle East & Africa
5.7. By Company Market Share (%), 2022
6. Global Non-Small Cell Lung Cancer Market Outlook, By Region, 2016-2030F
6.1. North America*
6.1.1.1. By Value
6.1.1.2. By Volume
6.1.2.By Type
6.1.2.1. Squamous Cell Carcinoma
6.1.2.2. Large Cell Carcinoma
6.1.2.3. Adenocarcinoma
6.1.2.4. Others
6.1.3.By Treatment Type
6.1.3.1. Chemotherapy
6.1.3.2. Targeted Therapy
6.1.3.3. Immunotherapy
6.1.4.By Drug Class
6.1.4.1. Angiogenesis Inhibitor
6.1.4.2. Epidermal Growth Factor Receptor Blocker
6.1.4.3. Kinase Inhibitor
6.1.4.4. Microtubule Stabilizer
6.1.4.5. Folate Antimetabolites
6.1.4.6. PD-1/ PD-L1 Inhibitor
6.1.5.By Distribution Channel
6.1.5.1. Hospital Pharmacy
6.1.5.2. Drug Store & Retail Pharmacy
6.1.5.3. Online Pharmacy
6.1.6.United States*
6.1.6.1. Market Size & Forecast
6.1.6.1.1. By Value
6.1.6.1.2. By Volume
6.1.6.2. By Type
6.1.6.2.1. Squamous Cell Carcinoma
6.1.6.2.2. Large Cell Carcinoma
6.1.6.2.3. Adenocarcinoma
6.1.6.2.4. Others
6.1.6.3. By Treatment Type
6.1.6.3.1. Chemotherapy
6.1.6.3.2. Targeted Therapy
6.1.6.3.3. Immunotherapy
6.1.6.4. By Drug Class
6.1.6.4.1. Angiogenesis Inhibitor
6.1.6.4.2. Epidermal Growth Factor Receptor Blocker
6.1.6.4.3. Kinase Inhibitor
6.1.6.4.4. Microtubule Stabilizer
6.1.6.4.5. Folate Antimetabolites
6.1.6.4.6. PD-1/ PD-L1 Inhibitor
6.1.6.5. By Distribution Channel
6.1.6.5.1. Hospital Pharmacy
6.1.6.5.2. Drug Store & Retail Pharmacy
6.1.6.5.3. Online Pharmacy
6.1.7.Canada
6.1.8.Mexico
*All segments will be provided for all regions and countries covered
6.2. Europe
6.2.1.Germany
6.2.2.France
6.2.3.Italy
6.2.4.United Kingdom
6.2.5.Russia
6.2.6.Netherlands
6.2.7.Spain
6.2.8.Turkey
6.2.9.Poland
6.3. South America
6.3.1.Brazil
6.3.2.Argentina
6.4. Asia-Pacific
6.4.1.India
6.4.2.China
6.4.3.Japan
6.4.4.Australia
6.4.5.Vietnam
6.4.6.South Korea
6.4.7.Indonesia
6.4.8.Philippines
6.5. Middle East & Africa
6.5.1.Saudi Arabia
6.5.2.UAE
6.5.3.South Africa
7. Market Mapping, 2022
7.1. By Type
7.2. By Treatment Type
7.3. By Drug Class
7.4. By Distribution Channel
7.5. By Region
8. Macro Environment and Industry Structure
8.1. Supply Demand Analysis
8.2. Import Export Analysis – Volume and Value
8.3. Supply/Value Chain Analysis
8.4. PESTEL Analysis
8.4.1.Political Factors
8.4.2.Economic System
8.4.3.Social Implications
8.4.4.Technological Advancements
8.4.5.Environmental Impacts
8.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
8.5. Porter’s Five Forces Analysis
8.5.1.Supplier Power
8.5.2.Buyer Power
8.5.3.Substitution Threat
8.5.4.Threat from New Entrant
8.5.5.Competitive Rivalry
9. Market Dynamics
9.1. Growth Drivers
9.2. Growth Inhibitors (Challenges, Restraints)
10. Regulatory Framework and Innovation
10.1. Clinical Trials
10.2. Patent Landscape
10.3. Regulatory Approvals
10.4. Innovations/Emerging Technologies
11. Key Players Landscape
11.1. Competition Matrix of Top Five Market Leaders
11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
11.4. SWOT Analysis (For Five Market Players)
11.5. Patent Analysis (If Applicable)
12. Pricing Analysis
13. Case Studies
14. Key Players Outlook
14.1.1. Company Details
14.1.2. Key Management Personnel
14.1.3. Products & Services
14.1.4. Financials (As reported)
14.1.5. Key Market Focus & Geographical Presence
14.2. F. Hoffmann-La Roche Ltd.
14.3. Bristol-Myers Squibb Company
14.4. Pfizer Inc.
14.5. AstraZeneca
14.6. Eli Lilly and Company
14.7. Merck & Co., Inc.
14.8. Boehringer Ingelheim International GmbH
14.9. Sanofi
14.10. Astellas Pharma Inc.
14.11. Takeda Pharmaceutical Company Limited
14.12. Bayer AG
14.13. Eli Lilly and Company
14.14. GlaxoSmithKline plc.
14.15. Agennix AG.
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
15. Strategic Recommendations
16. About Us & Disclaimer
List of Figures: Global Non-Small Cell Lung Cancer Market
Figure 1. Global Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 2. Global Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 3. Global Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 4. Global Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 5. Global Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 6. Global Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 7. Global Non-Small Cell Lung Cancer Market Share, By Region, In USD Billion, 2016-2030F
Figure 8. North America Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 9. North America Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 10. North America Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 11. North America Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 12. North America Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 13. North America Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 14. North America Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
Figure 15. United States Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 16. United States Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 17. United States Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 18. United States Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 19. United States Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 20. United States Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 21. Canada Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 22. Canada Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 23. Canada Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 24. Canada Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 25. Canada Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 26. Canada Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 27. Mexico Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 28. Mexico Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 29. Mexico Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 30. Mexico Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 31. Mexico Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 32. Mexico Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 33. Europe Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 34. Europe Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 35. Europe Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 36. Europe Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 37. Europe Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 38. Europe Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 39. Europe Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
Figure 40. Germany Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 41. Germany Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 42. Germany Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 43. Germany Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 44. Germany Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 45. Germany Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 46. France Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 47. France Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 48. France Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 49. France Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 50. France Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 51. France Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 52. Italy Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 53. Italy Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 54. Italy Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 55. Italy Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 56. Italy Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 57. Italy Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 58. United Kingdom Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 59. United Kingdom Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 60. United Kingdom Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 61. United Kingdom Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 62. United Kingdom Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 63. United Kingdom Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 64. Russia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 65. Russia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 66. Russia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 67. Russia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 68. Russia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 69. Russia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 70. Netherlands Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 71. Netherlands Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 72. Netherlands Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 73. Netherlands Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 74. Netherlands Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 75. Netherlands Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 76. Spain Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 77. Spain Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 78. Spain Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 79. Spain Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 80. Spain Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 81. Spain Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 82. Turkey Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 83. Turkey Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 84. Turkey Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 85. Turkey Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 86. Turkey Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 87. Turkey Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 88. Poland Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 89. Poland Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 90. Poland Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 91. Poland Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 92. Poland Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 93. Poland Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 94. South America Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 95. South America Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 96. South America Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 97. South America Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 98. South America Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 99. South America Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 100. South America Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
Figure 101. Brazil Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 102. Brazil Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 103. Brazil Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 104. Brazil Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 105. Brazil Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 106. Brazil Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 107. Argentina Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 108. Argentina Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 109. Argentina Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 110. Argentina Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 111. Argentina Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 112. Argentina Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 113. Asia-Pacific Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 114. Asia-Pacific Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 115. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 116. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 117. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 118. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 119. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
Figure 120. India Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 121. India Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 122. India Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 123. India Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 124. India Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 125. India Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 126. China Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 127. China Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 128. China Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 129. China Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 130. China Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 131. China Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 132. Japan Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 133. Japan Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 134. Japan Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 135. Japan Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 136. Japan Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 137. Japan Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 138. Australia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 139. Australia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 140. Australia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 141. Australia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 142. Australia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 143. Australia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 144. Vietnam Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 145. Vietnam Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 146. Vietnam Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 147. Vietnam Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 148. Vietnam Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 149. Vietnam Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 150. South Korea Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 151. South Korea Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 152. South Korea Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 153. South Korea Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 154. South Korea Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 155. South Korea Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 156. Indonesia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 157. Indonesia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 158. Indonesia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 159. Indonesia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 160. Indonesia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 161. Indonesia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 162. Philippines Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 163. Philippines Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 164. Philippines Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 165. Philippines Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 166. Philippines Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 167. Philippines Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 168. Middle East & Africa Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 169. Middle East & Africa Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 170. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 171. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 172. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 173. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 174. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
Figure 175. Saudi Arabia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 176. Saudi Arabia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 177. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 178. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 179. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 180. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 181. UAE Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 182. UAE Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 183. UAE Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 184. UAE Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 185. UAE Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 186. UAE Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 187. South Africa Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
Figure 188. South Africa Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
Figure 189. South Africa Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
Figure 190. South Africa Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
Figure 191. South Africa Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
Figure 192. South Africa Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 194. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 195. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2022
Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022
List of Tables: Global Non-Small Cell Lung Cancer Market
Table 1. Pricing Pivot and Marginal Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects
Frequently Asked Questions
What regions are covered in the global non-small cell lung cancer market final report?
Who are the key players operating in global non-small cell lung cancer market?
What are the major drivers influencing the growth of global non-small cell lung cancer market?
What is the market size and growth rate of the global non-small cell lung cancer market?
See Related Reports
Global Coffee Market Assessment, Opportunities and Forecast, 2017-2031F
Global coffee market is expected to experience growth due to consumers’ increasing preference for organic and premium coffee that offers freshness, superior quality of beans and roasts, and unique flavor profile. Additionally, the product innovation,....Read More
Published on
July 2024
4,500
Global Home Theater System Market Assessment, Opportunities and Forecast, 2017-2031F
Global home theater system market is expected to experience growth due to technological advancements, increasing disposable incomes, rising demand for high-definition content, integration with smart home systems, and the surge in streaming services p....Read More
Published on
July 2024
4,500
Global Baby Food Market Assessment, Opportunities and Forecast, 2017-2031F
Global baby food market is expected to experience growth due to factors such as consumers’ increasing awareness of the nutrients which are essential for babies development and introduction of wide variety of baby foods in the market from milk powders....Read More
Published on
July 2024
4,500
Global Isoflavones Market Assessment, Opportunities and Forecast, 2017-2031F
Global isoflavones market is expected to experience growth due to increasing consumer health awareness, rising demand for functional foods and nutraceuticals, advancements in extraction technologies, and expanding applications in cosmetics, pharmaceu....Read More
Published on
July 2024
4,500
Purchase Options
USD ($)
i
3,000
i
4,500
i
5,700
i
8,200
Tired of Searching?
Looking for Customization?
Some other doubt?
Need insights from a cohort?
REACH US
